Genzyme and the International Center for Genetic Engineering and Biotechnology Form Collaboration to Advance Treatments for Neglected Diseases

Release Date:
Monday, November 17, 2008 4:05 pm EST

Terms:
Dateline City: CAMBRIDGE, Mass. & TRIESTE, Italy

CAMBRIDGE, Mass. & TRIESTE, Italy--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ), a global leader in biotechnology, and the International Center for Genetic Engineering and Biotechnology (ICGEB), a not-for-profit research and development (R&D) organization, announced today a new research collaboration to advance treatments for neglected diseases. The collaboration between Genzyme and ICGEB will initially focus on the development of new, improved treatments for malaria, a debilitating infectious disease of developing countries.

ICGEB and Genzyme scientists are currently targeting Plasmodium falciparum and Plasmodium vivax, increasingly resistant parasites that cause up to 65 percent of malaria in India. ICGEB has already begun to identify promising targets that, with the drug development expertise of Genzyme, could lead to drug compounds effective against malaria. The research will take place both in ICGEB’s laboratories in New Delhi, India and in Genzyme’s facilities in Waltham, Mass., U.S.A. Under the agreement, scientists from Genzyme and ICGEB are expected to work in each other’s laboratories from time to time. The collaboration includes an innovative approach to intellectual property rights, providing ICGEB rights to commercial uses within the field of neglected disease on a royalty-free basis.

Both organizations bring strong capabilities in biotechnology research and drug development. The ICGEB is a premier global research organization, with the mandate to use biotechnology to find solutions to problems of the developing world. Funded in part by the Department of Biotechnology of the Indian Ministry of Science and Technology and the Italian Ministry of Foreign Affairs, it conducts innovative research in life sciences and strengthens the research capabilities of its 57 member countries through training, funding programs and advisory services.

Genzyme is one of the world’s leading biotechnology companies, and uses the most advanced technologies in the life sciences to develop treatments for people with serious diseases. The company supports efforts to discover and advance novel treatments for neglected diseases such as malaria, Chagas disease and sleeping sickness through its Humanitarian Assistance for Neglected Diseases (HAND) initiative. The HAND initiative complements existing Genzyme programs that provide free medicines and help to build sustainable healthcare systems in developing countries. Genzyme established a formal presence in India last year to actively collaborate with private and public institutions in the country and the region.

“The biotechnology industry is in a remarkable position to address neglected diseases with novel technology, world-renowned scientists and research partners dedicated to a shared commitment to improve human health,” Henri A. Termeer, chairman and chief executive officer of Genzyme Corporation said. “The ICGEB is unlocking new approaches to preventing malaria, and Genzyme is ready build on their momentum and move these promising targets through the drug discovery process, ultimately bringing critical treatments to people at risk in the developing world. We look forward to building a productive, sustainable partnership with ICGEB.”

Virander Chauhan, director of ICGEB, New Delhi, said, “We are excited about this new collaboration. Combining ICGEB's domain knowledge in malaria with Genzyme’s expertise in drug development opens up new possibilities for the development of novel strategies to combat malaria.”

Welcoming the new initiative, Maharaj Bhan, secretary of the Department of Biotechnology of the Indian Ministry of Science and Technology, said, “This is an innovative new model for translational research through public-private partnerships. My best wishes to ICGEB and Genzyme for a fruitful and successful collaboration.”

About ICGEB

The International Centre for Genetic Engineering and Biotechnology (ICGEB) is an intergovernmental organization that is dedicated to advanced research and training in molecular biology and biotechnology with special regard to problems of developing countries. Established in 1987, ICGEB currently has 57 member countries with laboratories in New Delhi, India, Trieste, Italy and Cape Town, South Africa and a network of affiliated centers in its member states.

ICGEB, New Delhi conducts basic and applied research on problems related to human health and agriculture. In human health, research at ICGEB, New Delhi focuses on infectious diseases including malaria, HIV, tuberculosis, Hepatitis E, Hepatitis B and dengue. Research on malaria focuses on understanding the biology of the malaria parasite and its interaction with the host. This knowledge is used to pursue novel approaches to develop drugs and vaccines to combat malaria.

More information on ICGEB and its programs is available at www.icgeb.trieste.it

About Genzyme Corporation

One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of
people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Language:
English

Contact:
Media Contacts:
Genzyme Corporation
Lori Gorski, 617-768-9344
lori.gorski@genzyme.com
or
ICGB
Dr. Chetan Chitnis, +91 98104 00155
or
Investor Contact:
Genzyme Corporation
Patrick Flanigan, 617-768-6563

Ticker Slug:
Ticker: GENZ
Exchange: NASDAQ
ISIN: US3729171047